Answers are grounded in this paper and cite their sources.
Background Cyclophosphamide (CP), in addition to being a commonly used chemotherapeutic agent, can cause hepatotoxicity through oxidative stress, inflammation, and apoptosis. Bromelain (BRM) is a natural enzyme complex with antioxidant, anti-inflammatory, and proteolytic properties.Objective This study aimed to evaluate the potential hepatoprotective effects of BRM in experimental liver injury induced by CP in rats at biochemical, molecular, and histopathological levels.Materials and methods The study was conducted using four experimental groups: control, CP, CP + BRM20, and CP + BRM40. Experimental hepatotoxicity was induced by a single intraperitoneal dose of CP (200 mg/kg) on the 4th day of the study. BRM was administered orally at doses of 20 and 40 mg/kg for 10 days. Oxidative stress, inflammation, and apoptosis markers were evaluated in liver tissue; additionally, serum liver function tests and histopathological examination were performed.Results CP administration increased lipid peroxidation (MDA) and DNA oxidation (8-OHdG) in liver tissue, while suppressing the antioxidant defense system (SOD, CAT, and GSH). In addition, the increase in levels of TNF-α, IL-1β, and IL-6 indicated an enhanced inflammatory response. CP also disrupted the Nrf2/Keap1/HO-1 pathway, promoting apoptosis by increasing the Bax/Bcl-2 ratio and the expression of caspase-3 and caspase-9. BRM administration significantly attenuated these changes, improved liver function parameters, and reduced histopathological damage. The protective effect was more pronounced in the high-dose BRM (40 mg/kg) group.Conclusion BRM demonstrated hepatoprotective potential by exhibiting antioxidant, anti-inflammatory, and anti-apoptotic effects against CP-induced hepatotoxicity.
No takes yet. Share an insight, caveat, or question.
Dönmez et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: